Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LRRC15


Brief Information

Name:Leucine-rich repeat-containing protein 15
Target Synonym:LRRC15,Leucine-rich repeat-containing protein 15,hLib,Leucine Rich Repeat Containing 15,Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog,LIB,Leucine-Rich Repeat Protein Induced By Beta Amyloid
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Preclinical

Product ListCompare or Buy

Part of Bioactivity data

Biotinylated Mouse LRRC15, His,AvitagBiotinylated Mouse LRRC15, His,Avitag (Cat. No. LR5-M82E6) ELISA bioactivity

Immobilized Biotinylated Mouse LRRC15, His,Avitag (Cat. No. LR5-M82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Samrotamab with a linear range of 0.1-1 ng/mL (QC tested).

Mouse LRRC15, His Tag (Cat. No. ) MALS images

The purity of Mouse LRRC15, His Tag (Cat. No. LR5-M5225) is more than 90% and the molecular weight of this protein is around 68-92 kDa verified by SEC-MALS.

Mouse LRRC15, His TagMouse LRRC15, His Tag (Cat. No. LR5-M5225) ELISA bioactivity

Immobilized Mouse LRRC15, His Tag (Cat. No. LR5-M5225) at 10 μg/mL (100 μL/well) can bind Samrotamab with a linear range of 1-10 ng/mL (QC tested).

Synonym Name

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib


LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Samrotamab vedotin ABBV-085; PR-1498487-MMAE Abbvie Inc Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message